Schmieder R (2022)
Publication Type: Journal article, Review article
Publication year: 2022
DOI: 10.1093/ndt/gfac189
Supported by several high-quality randomized controlled trials and registry analyses, catheter-based renal denervation is becoming an important adjunctive treatment modality for the safe and efficacious treatment of hypertension besides lifestyle modifications and antihypertensive medication. Renal denervation is of particular interest to nephrologists as the intervention may provide additional benefits to hypertensive people with chronic kidney disease (CKD), a condition typically characterized by sympathetic hyperactivity. A growing body of clinical evidence supports the safety and efficacy of renal denervation in this difficult-to-control population. In addition, preclinical and clinical research works indicate potential nephroprotective effects in CKD patients. The current review examines recent research on renal denervation with a focus on renal disease and assesses the latest findings and their implications from a nephrologist's perspective.
APA:
Schmieder, R. (2022). Renal denervation in patients with chronic kidney disease: current evidence and future perspectives. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfac189
MLA:
Schmieder, Roland. "Renal denervation in patients with chronic kidney disease: current evidence and future perspectives." Nephrology Dialysis Transplantation (2022).
BibTeX: Download